Jena Rahul, Jain Ruchi, Muralidharan Suchitra, Yanamala Vijaya Lakshmi, Zubair Zainab, Kantamaneni Ketan, Jalla Krishi, Renzu Mahvish, Alfonso Michael
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Diagnostic Radiology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2021 Oct 25;13(10):e19035. doi: 10.7759/cureus.19035. eCollection 2021 Oct.
Parkinson's disease (PD) is one of the most common neurodegenerative diseases with a high rate of morbidity. It is associated with dopaminergic neuron loss and is fairly common in the elderly population. Recently, there has been a growing interest in the role of the gut microbiome in the pathogenesis of PD and thus studies addressing the methods to modulate the microbiota are becoming increasingly popular. Fecal microbiota transplant (FMT) is one of these methods and is effective in certain intestinal and extraintestinal conditions. This review aims to talk about gastrointestinal dysbiosis and how the reconstruction of this microbiome via FMT could potentially be used as a treatment modality in the future. We went through various studies and collected data relevant to our topic from the previous five years. The studies selected include reviews, observational studies, animal studies, case reports, and some grey literature. We concluded that although it has great potential as a therapeutic modality in the future, it is limited by several factors such as variability among the results of most clinical studies and the lack of large sample sizes. Therefore, there is a need for high-quality clinical trials with larger sample sizes to gather enough clinical evidence so that FMT can qualify as a widely recommended therapeutic measure.
帕金森病（PD）是最常见的神经退行性疾病之一，发病率很高。它与多巴胺能神经元丢失有关，在老年人群中相当常见。最近，肠道微生物群在PD发病机制中的作用越来越受到关注，因此，探讨调节微生物群方法的研究越来越受欢迎。粪便微生物群移植（FMT）是其中一种方法，在某些肠道和肠道外疾病中有效。本综述旨在探讨胃肠道生态失调以及通过FMT重建这种微生物群如何有可能在未来用作一种治疗方式。我们查阅了各种研究，并收集了过去五年与我们主题相关的数据。所选研究包括综述、观察性研究、动物研究、病例报告以及一些灰色文献。我们得出的结论是，尽管它作为一种未来的治疗方式具有很大潜力，但它受到几个因素的限制，如大多数临床研究结果的变异性以及样本量不足。因此，需要进行更大样本量的高质量临床试验，以收集足够的临床证据，使FMT有资格成为广泛推荐的治疗措施。
